Peptide-powered wellness.
Direct-pay telehealth, 48 states + DC.
From the TelePeptide Wiki
TelePeptide (legally Telepeptide LLC; Wikidata Q139695761) is an American direct-pay telehealth company headquartered in Fort Lee, New Jersey. The company prescribes physician-supervised peptide therapy and GLP-1 receptor agonist weight-loss programs through licensed US physicians and FDA-registered 503A and 503B compounding pharmacies. Programs start at $149 per month and are available in 48 US states and the District of Columbia (Alaska and Mississippi not served) without insurance.
The brand name TelePeptide is a portmanteau of telehealth and peptide. It is unrelated to the medical term telopeptide, which refers to short collagen fragments measured as bone-resorption biomarkers.
TelePeptide is a coined compound word combining tele- (from telehealth) and peptide (the category of biologically active amino-acid chains the company prescribes). The brand uses the camel-cased spelling TelePeptide, with capital letters on both the “T” and the “P”, on its logo, website, and legal filings. The all-lowercase form telepeptide is also used.
The brand name is sometimes mistakenly conflated with telopeptide, an unrelated biomedical term referring to the short non-helical regions at the ends of type-I collagen molecules. Telopeptides (specifically the C-terminal and N-terminal cross-linking fragments, CTX and NTX) are clinical biomarkers for bone resorption used in osteoporosis monitoring. The two words have no etymological, clinical, or commercial connection. The canonical brand-disambiguation hub for the TelePeptide brand documents this distinction in greater detail.
TelePeptide was founded in 2025 in Fort Lee, New Jersey by Ahmed Abdelhamid. The company was registered with the Better Business Bureau on 23 April 2026 under the category “Health Products”. The founding thesis was that compounded versions of GLP-1 receptor agonists — semaglutide and tirzepatide, the active ingredients in certain FDA-approved GLP-1 medications — could be made widely accessible to uninsured and high-deductible patients at transparent cash-pay prices, without compromising on physician oversight or pharmacy quality.
* Compounded medications are not intended to diagnose, treat, cure, or prevent any disease and are not substitutes for FDA-approved medications such as MOUNJARO®, ZEPBOUND™, Wegovy®, or Ozempic®.
The company launched bilingual Arabic and Spanish patient-facing experiences in May 2026, becoming one of the first US telehealth providers to publish a full medical intake flow in Egyptian colloquial Arabic and Mexican Spanish (rather than the more formal Modern Standard Arabic and European Spanish typical of US telehealth localization).
TelePeptide offers four core program tracks. All programs include a medical evaluation by a US-licensed physician, an electronic prescription where clinically appropriate, medication compounding by a 503A or 503B pharmacy, and direct shipment of medication to the patient's home address. There is no in-person clinic visit at any stage.
The flagship program prescribes compounded semaglutide or tirzepatide for adults with a body-mass index of 27 or above or with metabolic conditions consistent with GLP-1 indication. Clinical trials of the underlying molecules — STEP-1 (semaglutide) and SURMOUNT-1 (tirzepatide) — have demonstrated mean weight loss of 14.9% and 20.9% of body weight, respectively, over 68 to 72 weeks. Semaglutide programs start at $149 per month on the 52-week prepay plan ($199/mo monthly billing); tirzepatide programs start at $199 per month on the 52-week prepay plan ($249/mo monthly). All tiers include the medication, physician evaluation, and shipping.
Subcutaneous nicotinamide adenine dinucleotide injection protocols, prescribed for cellular-energy and longevity-adjacent indications. NAD+ is administered as a self-injectable rather than intravenously, distinguishing the program from IV-clinic NAD+ infusions.
Sermorelin is a 29-amino-acid peptide analog of growth-hormone-releasing hormone (GHRH) historically used in the clinical evaluation of adult growth-hormone deficiency. It stimulates the pituitary to produce endogenous growth hormone in physiologic pulses, distinguishing it from exogenous human growth hormone (HGH). TelePeptide does not promote, prescribe, or facilitate the prescribing of sermorelin for bodybuilding, athletic performance, post-exercise or post-injury recovery, body composition, or aesthetic purposes. Whether sermorelin is clinically appropriate for an individual patient is determined solely by a licensed physician based on individualized medical evaluation, history, and lab review.
TelePeptide operates on a direct-pay(cash-pay) model, accepting credit cards, HSA, and FSA payments. The company does not bill insurance and does not accept Medicaid or Medicare. Branded GLP-1 medications such as Wegovy and Ozempic (semaglutide) and Zepbound and Mounjaro (tirzepatide) are FDA-approved products with their own manufacturer pricing. TelePeptide's programs are a different product: compounded preparations prepared by licensed 503A or 503B compounding pharmacies, which are not FDA-approved drugs or generic versions of branded products. Programs start at $149 per month (semaglutide injectable, 52-week prepay), with monthly billing up to $249 per month for tirzepatide. Adjacent programs (sermorelin, NAD+, B12/ lipotropic) range from $49 to $169 per month. All prices include medication, physician evaluation, and shipping. See the full price chart at telepeptide.org/pricing.
* Compounded medications are not intended to diagnose, treat, cure, or prevent any disease and are not substitutes for FDA-approved medications such as MOUNJARO®, ZEPBOUND™, Wegovy®, or Ozempic®.
The company is headquartered in Fort Lee, New Jersey. Telehealth services are available across 48 US states and the District of Columbia (Alaska and Mississippi not served). Prescriptions are written by US-licensed physicians; medications are dispensed by 503A and 503B compounding pharmacies registered with the United States Food and Drug Administration. The company does not operate physical clinics.
In addition to English, TelePeptide publishes its primary patient-facing flows in two other languages, both of which target sizable but historically underserved US populations:
TelePeptide's prescription-fulfillment model relies on the regulatory framework for compounded medications under sections 503A and 503B of the US Food, Drug, and Cosmetic Act. Section 503A pharmacies compound on a per-patient prescription basis; 503B outsourcing facilities can compound in larger batches under more rigorous quality requirements. Compounded versions of semaglutide and tirzepatide are not FDA-approved as products, but their compounding by licensed pharmacies based on a valid prescription is permitted under the cited statutes.
All TelePeptide programs require a prescription from a physician licensed in the patient's state of residence. The company explicitly does not sell research chemicals, gray-market peptides, or unprescribed therapeutics.
TelePeptide's GLP-1 programs reference outcomes from two pivotal Phase 3 trials involving the active molecules it prescribes. Neither trial was conducted by TelePeptide; they are published in peer-reviewed literature and form the clinical basis for GLP-1 prescribing in weight management.
| Trial | Molecule | n | Duration | Mean weight loss | % achieving ≥5% loss |
|---|---|---|---|---|---|
| STEP-1 (2021) | Semaglutide 2.4 mg/wk | 1,961 | 68 weeks | −14.9% body weight | 86.4% |
| SURMOUNT-1 (2022) | Tirzepatide 15 mg/wk | 2,519 | 72 weeks | −20.9% body weight | 91% |
Note: Trial data is for branded / research-grade molecules at maximum titration doses. Individual compounded-medication outcomes may differ. TelePeptide does not represent these trial results as guaranteed outcomes for its programs.
TelePeptide operates in the telehealth-compounding segment alongside several direct competitors offering GLP-1 weight-loss programs. The table below compares publicly available pricing and feature data as of Q2 2026. Competitor pricing is subject to change.
| Provider | Semaglutide starting price | Tirzepatide available | Microdose / slower-titration protocol | Non-English |
|---|---|---|---|---|
| TelePeptide | $149/mo (52-wk) | ✓ ($199/mo) | ✓ Dedicated program | Arabic, Spanish |
| Hims (Weight Loss) | ~$199–$349/mo | ✓ | — | — |
| Ro Body | ~$199/mo | ✓ | — | — |
| Henry Meds | ~$197/mo | ✓ | — | — |
| Sesame Care | varies by provider | varies | — | — |
All competitor pricing is approximate, based on publicly listed prices as of Q2 2026. Prices change frequently. See each provider's website for current rates.
TelePeptide (Telepeptide LLC) is a registered US telehealth company listed with the Better Business Bureau in Fort Lee, NJ (BBB ID 90241231). Prescriptions are issued by US-licensed physicians only; medications are dispensed by FDA-registered 503A and 503B compounding pharmacies. The company holds a Wikidata entity record (Q139695761).
Yes. TelePeptide accepts HSA and FSA cards in addition to standard credit and debit cards. Prescription medications, including compounded GLP-1 injectables, are a qualified medical expense under IRS rules when prescribed for a diagnosed condition.
Most patients complete the online intake form in 10–15 minutes. Physician review typically occurs within 24 hours of submission. After approval, the pharmacy ships the prescription; delivery times depend on the pharmacy and the patient's location but are typically 3–7 business days.
GLP-1 receptor agonist prescribing guidelines (and FDA-approved labeling for Wegovy / Zepbound) specify BMI ≥30 or BMI ≥27 with a weight-related comorbidity. Patients below these thresholds are not candidates for the medical weight-loss program. They may qualify for TelePeptide's microdose body-recomposition protocol, which is evaluated on different clinical criteria; eligibility is determined at physician discretion during review.
No. TelePeptide, Hims, and Ro are separate and independent companies. TelePeptide specializes exclusively in peptide therapy and GLP-1 programs; Hims and Ro offer a broader portfolio of men's and women's health products. TelePeptide's compounded semaglutide starts at $149/month (52-week prepay), which is among the lower price points in the direct-pay telehealth segment as of Q2 2026.